HUP9603298A2 - Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása, a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása, a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP9603298A2
HUP9603298A2 HU9603298A HUP9603298A HUP9603298A2 HU P9603298 A2 HUP9603298 A2 HU P9603298A2 HU 9603298 A HU9603298 A HU 9603298A HU P9603298 A HUP9603298 A HU P9603298A HU P9603298 A2 HUP9603298 A2 HU P9603298A2
Authority
HU
Hungary
Prior art keywords
pipe powder
alkylene
diseases
piper
general formula
Prior art date
Application number
HU9603298A
Other languages
English (en)
Inventor
Tetsuya Fukazawa
Koki Ishibashi
Kazuhiro Ito
Hitoshi Kurata
Katsuyoshi Nakajima
Takahide Nishi
Takeshi Yamaguchi
Original Assignee
Sankyo Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co. Ltd. filed Critical Sankyo Co. Ltd.
Publication of HU9603298D0 publication Critical patent/HU9603298D0/hu
Publication of HUP9603298A2 publication Critical patent/HUP9603298A2/hu
Publication of HUP9603298A3 publication Critical patent/HUP9603298A3/hu
Publication of HU224225B1 publication Critical patent/HU224225B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány őlyan új, (I) általánős képletű heterőciklűsősvegyületekre, ezek (Ia) általánős képletű kvaternerammóniűmszármazékaira, tővábbá gyógyászatilag elfőgadható sóikra ésésztereikre vőnatkőzik, amelyek tachikinin receptőr antagőnistahatásúak mind az Nk1-, mind az Nk2-receptőrők vőnatkőzásában Az (I) és(Ia) általánős képletben L jelentése -N(R3)- vagy -C(R4)(R5)-általánős képletű csőpőrt, előnyösen (XLIII) általánős képletűcsőpőrt, R1 és R2 adőtt esetben szűbsztitűált karbőciklűsősarilcsőpőrtőt vagy arőms heterőciklűsős csőpőrtőt jelent, R7 jelentésealkilcsőpőrt, A jelentése metilén-, karbőnil- vagy szűlfőnilcsőpőrt, Bjelentése kémiai kötés vagy alkilén- vagy alkeniléncsőpőrt, Djelentése őxigén- vagy kénatőm. E jelentése alkilén-, ciklőalkán-diil-vagy ciklőalkán-diil-metilcsőpőrt, és G jelentése alkilén- vagyalkeniléncsőpőrt, I jelentése alkiléncsőpőrt. A találmány szerinti vegyületek felhasználhatók példáűl a következőbetegségek gyógyításában: közpőnti idegrendszeri megbetegedések,gyűlladásők, allergiák, bőrbetegségek, kórős imműnreakciók, keringésibetegségek és húgyhólyag működési rendellenességek. ŕ
HU9603298A 1995-12-01 1996-11-29 Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására HU224225B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31382895 1995-12-01
JP33636995 1995-12-25
JP29686996 1996-11-08

Publications (4)

Publication Number Publication Date
HU9603298D0 HU9603298D0 (en) 1997-01-28
HUP9603298A2 true HUP9603298A2 (hu) 1998-09-28
HUP9603298A3 HUP9603298A3 (en) 1999-10-28
HU224225B1 HU224225B1 (hu) 2005-06-28

Family

ID=27338095

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9603298A HU224225B1 (hu) 1995-12-01 1996-11-29 Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására

Country Status (19)

Country Link
US (2) US6159967A (hu)
EP (1) EP0776893B1 (hu)
CN (1) CN1142932C (hu)
AT (1) ATE213738T1 (hu)
AU (1) AU719158B2 (hu)
CA (1) CA2191815C (hu)
CZ (1) CZ288498B6 (hu)
DE (1) DE69619479T2 (hu)
DK (1) DK0776893T3 (hu)
ES (1) ES2170211T3 (hu)
HK (1) HK1011366A1 (hu)
HU (1) HU224225B1 (hu)
IL (1) IL119729A (hu)
MX (1) MX9606082A (hu)
NO (1) NO308300B1 (hu)
NZ (1) NZ299859A (hu)
PT (1) PT776893E (hu)
RU (1) RU2135494C1 (hu)
TW (1) TW367327B (hu)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU224225B1 (hu) * 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
IL132962A0 (en) * 1997-05-30 2001-03-19 Sankyo Co Salts of an optically-active sulfoxide derivative pharmaceutical compositions containing the same and the use thereof
HUP0004321A3 (en) 1997-12-04 2002-04-29 Sankyo Co Alicyclic acylated heterocyclic derivatives and pharmaceutical compositions containing the same
PT1057827E (pt) * 1998-01-23 2003-11-28 Sankyo Co Derivados da espiropiperidina
AU1684300A (en) * 1998-12-10 2000-06-26 Sankyo Company Limited Cyclohexylpiperidine derivatives
FR2791346B3 (fr) 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
WO2001029027A1 (fr) * 1999-10-22 2001-04-26 Sankyo Company, Limited Dérivés de 2-alcoxybenzène
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
EP1299393A2 (en) 2000-07-11 2003-04-09 Bristol-Myers Squibb Pharma Company 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
JP2004067673A (ja) * 2002-06-11 2004-03-04 Sankyo Co Ltd 環状チオエーテル類の製造法及びその合成中間体
WO2003104240A1 (ja) * 2002-06-11 2003-12-18 三共株式会社 環状チオエーテル類の製造法及びその合成中間体
US7396930B2 (en) 2002-06-11 2008-07-08 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
CA2503520A1 (en) * 2002-10-24 2004-05-06 Sankyo Company Limited Process for producing optically active sulfoxide
US7560549B2 (en) * 2004-02-25 2009-07-14 Sankyo Company, Limited Sulfonyloxy derivatives
CN1922173A (zh) 2004-02-25 2007-02-28 三共株式会社 茚满醇衍生物
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
RU2007109794A (ru) * 2004-08-19 2008-09-27 Вертекс Фармасьютикалз, Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US20080288019A1 (en) * 2007-01-31 2008-11-20 Adam Heller Electrochemical management of pain
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
PL2346837T3 (pl) 2008-06-26 2015-07-31 Resverlogix Corp Sposoby wytwarzania pochodnych chinazolinonu
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
SI2421533T1 (sl) 2009-04-22 2019-01-31 Resverlogix Corp. Nova protivnetna sredstva
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CN103945848B (zh) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 被取代的喹唑啉酮的口服即释制剂
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
JPWO2020101017A1 (ja) * 2018-11-15 2021-09-30 国立大学法人九州大学 Ｉｌ−３１介在性疾患の予防又は治療剤及び医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
WO1993012115A1 (en) 1991-12-18 1993-06-24 Gruppo Lepetit S.P.A. 7'-amino-naphthazarin antibiotic derivatives
WO1994017045A1 (en) * 1993-01-28 1994-08-04 Merck & Co., Inc. Spiro-substituted azacycles as tachykinin receptor antagonists
ATE158580T1 (de) * 1993-05-06 1997-10-15 Merrell Pharma Inc Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
AU680020B2 (en) 1993-06-07 1997-07-17 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
AU2223495A (en) * 1994-04-15 1995-11-10 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729952B1 (fr) 1995-01-30 1997-04-18 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
HU224225B1 (hu) * 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
JP3192631B2 (ja) * 1997-05-28 2001-07-30 三共株式会社 飽和複素環化合物からなる医薬

Also Published As

Publication number Publication date
AU7406596A (en) 1997-06-05
HUP9603298A3 (en) 1999-10-28
US6448247B1 (en) 2002-09-10
DE69619479D1 (de) 2002-04-04
NO965125L (no) 1997-06-02
TW367327B (en) 1999-08-21
HU9603298D0 (en) 1997-01-28
NO308300B1 (no) 2000-08-28
DK0776893T3 (da) 2002-03-18
CZ352196A3 (en) 1997-06-11
CZ288498B6 (en) 2001-06-13
RU2135494C1 (ru) 1999-08-27
EP0776893A1 (en) 1997-06-04
IL119729A (en) 2001-07-24
HU224225B1 (hu) 2005-06-28
PT776893E (pt) 2002-06-28
CA2191815A1 (en) 1997-06-02
MX9606082A (es) 1998-08-30
EP0776893B1 (en) 2002-02-27
US6159967A (en) 2000-12-12
ES2170211T3 (es) 2002-08-01
HK1011366A1 (en) 1999-07-09
CA2191815C (en) 2005-05-10
NO965125D0 (no) 1996-12-02
CN1142932C (zh) 2004-03-24
AU719158B2 (en) 2000-05-04
CN1157286A (zh) 1997-08-20
NZ299859A (en) 1997-11-24
ATE213738T1 (de) 2002-03-15
DE69619479T2 (de) 2002-10-17
IL119729A0 (en) 1997-03-18

Similar Documents

Publication Publication Date Title
HUP9603298A2 (hu) Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása, a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9801887A2 (hu) CCR-3 receptor antagonista hatású gyűrűs aminszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
HUP0401567A2 (hu) CB1 receptor antagonista aktivitással rendelkező új 4,5-dihidro-1H-pirazol-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP9802323A2 (hu) Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
NZ506251A (en) Benzothiadiazine and benzothiadiazepine derivatives and their use as positive AMPA receptor modulators
ES2137998T3 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
ATE254618T1 (de) Spiro chinuclidin-derivate, ihre herstellung und verwendung
JPH07502739A (ja) ５−ｈｔレセプター拮抗物質としてのピペラジン誘導体
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
HUP0302966A2 (hu) Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO974734L (no) Nye arylglycinamidderivater, fremgangsmåte for deres fremstilling og farmasaöytiske blandinger inneholdende disse forbindelser
HUP0203874A2 (hu) Helyettesített 4-(fenil-N-alkil)piperazin és piperidinszármazékok és alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények
RU2004121688A (ru) 7-аминобензотиазольные производные в качестве лигандов аденозинового рецептора
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE69316067D1 (de) Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus
CA2636601C (en) Novel melatonin ligands having antidepressant activity as well as sleep inducing properties
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
BR0308780A (pt) Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica
DE69429570D1 (de) Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
HUP0202534A2 (hu) Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények
HUP0301551A2 (hu) 5-HT3 és idegi nikotinsav receptor antagonista 1-amino-alkil-ciklohexán származékok új alkalmazása
ATE8990T1 (de) 6,7-benzomorphan-derivate, verfahren zu ihrer herstellung, diese derivate enthaltende pharmazeutische zusammensetzungen und ihre verwendung als pharmazeutika.
MXPA03011563A (es) Derivados de benzoxazepina y su uso como estimuladores de receptor ampa.
DE60130628D1 (de) Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050509

MM4A Lapse of definitive patent protection due to non-payment of fees